FDA Approved: PRALUENT — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved Regeneron's supplemental application for PRALUENT (alirocumab), confirming expanded regulatory authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Heterozygous Familial Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

SUPPL AP for PRALUENT (ALIROCUMAB)